Published May 7, 2014 | Version v1
Journal article Metadata-only

CCL21 Cancer Immunotherapy

Creators

  • 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, 37-131 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095 (United States)
  • 2. Clinical and Translational Science Institute, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 (United States)
  • 3. UCLA Head and Neck Cancer Program, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 (United States)
  • 4. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 (United States)
  • 5. Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 (United States)
  • 6. Veterans' Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073 (United States)

Description

Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer

Availability note (English)

Available from http://dx.doi.org/10.3390/cancers6021098; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074818

Additional details

Identifiers

URL
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074818;
DOI
10.3390/cancers6021098;

Publishing Information

Journal Title
Cancers (Basel)
Journal Volume
6
Journal Issue
2
Journal Page Range
p. 1098-1110
ISSN
2072-6694

INIS

Country of Publication
Switzerland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47006749
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
IMMUNOTHERAPY; LYMPHOKINES; NEOPLASMS; POLYMERS
Descriptors DEC
DISEASES; GROWTH FACTORS; MEDICINE; MITOGENS; ORGANIC COMPOUNDS; PROTEINS; THERAPY

Optional Information

Copyright
Copyright (c) 2014 by the authors
Notes
PMCID: PMC4074818; PMID: 24810425; PUBLISHER-ID: cancers-06-01098; OAI: oai:pubmedcentral.nih.gov:4074818; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).